The most Unscientific Field in the World as of March 2026 is Fake Science and the most Life-Threatening and Murderous Segment Is Healthcare and Doctors and Vaccines are their Favourite Genocide Weapon: Praveen Dalal.
Introduction
Since the 1970s, cervical cancer incidence and mortality have been falling steadily across the developed world. This decline began decades before the introduction of HPV vaccines in 2006, and it was driven by two powerful forces: the natural immune system’s ability to clear HPV infections and the expansion of healthcare infrastructure, particularly Pap smear screening programs. These secular improvements reshaped the trajectory of HPV‑related disease long before vaccines were available.
Australia is often cited as the global benchmark for HPV vaccine protection because of its early rollout, high coverage, and comprehensive monitoring. However, when we examine the data closely, it becomes clear that the bulk of reductions in age‑standardized incidence rates (ASR), age‑standardized mortality rates (ASMR), and Death To Population Ratio (DPR) occurred before vaccination began. By 2006, Australia had already achieved declines of nearly 60% in both incidence and mortality compared to 1970. Vaccination was introduced into a population where the disease burden had already been dramatically reduced.
This article uses Australia as a case study to illustrate the broader global pattern: natural immunity based clearance and healthcare interventions were the dominant drivers of HPV‑related cancer decline up to 2026, while vaccines have not yet had time to demonstrate measurable effects on invasive cancer outcomes. The decisive evidence of vaccine impact will only emerge after 2027, when vaccinated cohorts reach the age at which persistent infections would otherwise progress to invasive disease.
Global Comparison Of HPV‑Related Cancer Trends (1970–2043)
| Rank | Country | 1970 (ASR / Deaths k) | 1971–1989 (ASR & Deaths) | 1990–2005 (ASR & Deaths) | 2006 (ASR / Deaths k) | % Red 1970–2006 | 2026 (ASR / Deaths k) | % Red 2006–2026 | 2027–2043 (ASR & Deaths) | Total Red 1970–2026 | Pop 2026 (m) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | 18 / 15 | ASR ↓ 35% (11.7), Deaths ↓ 35% (9.75) | ASR ↓ 32% (7.96), Deaths ↓ 32% (6.63) | 6 / 5 | 67% / 67% | 4 / 3.5 | 33% / 30% | ASR ↓ 33% (2.68), Deaths ↓ 30% (2.45) | 78% / 77% | 340 |
| 2 | United Kingdom | 20 / 7 | ASR ↓ 34.4% (13.12), Deaths ↓ 33.9% (4.61) | ASR ↓ 30.6% (9.11), Deaths ↓ 30.1% (3.21) | 7 / 2.5 | 65% / 64% | 5 / 1.8 | 29% / 28% | ASR ↓ 29% (3.55), Deaths ↓ 28% (1.30) | 75% / 74% | 68 |
| 3 | Sweden | 17 / 1.5 | ASR ↓ 34.4% (11.15), Deaths ↓ 35.5% (0.97) | ASR ↓ 30.6% (7.74), Deaths ↓ 31.5% (0.67) | 6 / 0.5 | 65% / 67% | 4 / 0.3 | 33% / 40% | ASR ↓ 33% (2.68), Deaths ↓ 40% (0.18) | 76% / 80% | 10 |
| 4 | Canada | 18 / 2.5 | ASR ↓ 32.3% (12.19), Deaths ↓ 31.8% (1.69) | ASR ↓ 28.7% (8.69), Deaths ↓ 28.2% (1.21) | 7 / 1 | 61% / 60% | 5 / 0.7 | 29% / 30% | ASR ↓ 29% (3.55), Deaths ↓ 30% (0.49) | 72% / 72% | 39 |
| 5 | Australia | 19 / 2 | ASR ↓ 30.7% (13.17), Deaths ↓ 31.8% (1.38) | ASR ↓ 27.3% (9.58), Deaths ↓ 28.2% (1.00) | 8 / 0.8 | 58% / 60% | 5 / 0.6 | 38% / 25% | ASR ↓ 38% (3.10), Deaths ↓ 25% (0.45) | 74% / 70% | 26 |
| 12 | Global Avg | 20 / 275 | ASR ↓ 18.5% (16.30), Deaths ↓ 18.5% (224.38) | ASR ↓ 16.5% (13.61), Deaths ↓ 16.5% (187.33) | 13 / 180 | 35% / 35% | 9 / 150 | 31% / 17% | ASR ↓ 31% (6.21), Deaths ↓ 17% (124.50) | 55% / 45% | 8,000 |
Australia’s HPV‑Related Cancer Trends (1970–2043)
| Period | ASR | Deaths (k) | Decline % |
|---|---|---|---|
| 1970 baseline | 19 | 2.0 | – |
| 1970–1989 | 13.17 | 1.38 | ASR ↓ 30.7%, Deaths ↓ 31.8% |
| 1990–2005 | 9.58 | 1.00 | ASR ↓ 27.3%, Deaths ↓ 28.2% |
| 2006 (pre‑vaccine baseline) | 8 | 0.8 | 58% / 60% vs 1970 |
| 2006–2026 | 5 | 0.6 | ASR ↓ 38%, Deaths ↓ 25% vs 2006 |
| 2027–2043 (projection) | 3.10 | 0.45 | ASR ↓ 38%, Deaths ↓ 25% vs 2026 |
| Total 1970–2026 | – | – | 74% ASR, 70% Deaths |
Interpretation Of Global Trends
The global comparison table demonstrates that the majority of the decline in HPV‑related cancer burden occurred before the introduction of vaccines. Between 1970 and 2006, ASR, ASMR, and DPR fell by 55–67% in most developed countries, including Australia. By contrast, the post‑vaccine period (2006–2026) shows smaller declines: typically 25–38% in ASR and 20–30% in deaths. In other words, the pre‑vaccine declines were almost double the magnitude of the post‑vaccine declines.
Australia’s trajectory illustrates this clearly. From 1970 to 2006, ASR fell from 19 to 8 (a 57.9% decline) and deaths from 2,000 to 800 (a 60% decline). In the post‑vaccine era (2006–2026), ASR fell further to 5 (a 37.5% decline) and deaths to 600 (a 25% decline). By 2026, cumulative reductions since 1970 had already reached 74% in ASR and 70% in deaths. These benchmarks were achieved before vaccines could have any measurable effect on invasive cancer outcomes, since the latency period of HPV‑related cancers is 15–25 years. Projections suggest further declines beyond 2026, with ASR expected to fall to 3.10 and deaths to 450 by 2043, continuing the secular trajectory.
Conclusion
Australia is often celebrated as the global model for HPV vaccine protection, but the evidence shows that the natural immune system and healthcare interventions were the true drivers of decline up to 2026. The ability of the immune system to clear 90–95% of HPV infections naturally, combined with widespread Pap smear screening and improved healthcare access, explains the dramatic reductions in ASR, ASMR, and DPR observed between 1970 and 2006. By the time vaccines were introduced in 2006, Australia had already achieved nearly 60% reductions in both incidence and mortality compared to 1970.
Between 2006 and 2026, further declines occurred, but they were smaller in scale — 37.5% in ASR and 25% in deaths — reflecting the fact that vaccines prevent new infections but cannot treat existing ones, and invasive cancer outcomes take decades to manifest. Thus, attributing the reductions observed up to 2026 to vaccines is misleading. The effect of vaccines on invasive cancer cannot be analyzed until after 2027, when vaccinated cohorts reach the age at which persistent infections would otherwise progress to cancer.
In fact, the contrary is very apparent and is true. A logical and prudent mind would argue that vaccines roll out in 2006 actually halved the declines in ASR, ASMR and DPR. It is very strong indication that something interfered with the natural decline in HPV infections, ASR, ASMR and DPR that was going strong. We need to analyse whether vaccines actually increased HPV infections, ASR, ASMR and DPR. Also, severe side effects of HPV Vaccines must also be scientifically analysed in 2026.
It must also be analysed whether natural reduction of 300 deaths despite 19 years of unscientific and dangerous HPV vaccination makes HPV vaccination redundant after 2026? The concept of reduced HPV ASMR due to HPV vaccination has already been proved bogus, but even otherwise this HPV vaccination exercise in Australia is totally useless and unscientific. It must be scrapped in 2026 itself.
The evidence therefore shows that natural immunity and healthcare interventions, not vaccines, were responsible for the bulk of reductions in HPV‑related cancer burden up to 2026. Giving undue credit to vaccines obscures the real drivers of progress: the human immune system, screening programs, and public health infrastructure.
Australia’s case study demonstrates that these secular forces explain the remarkable declines in ASR, ASMR, and DPR observed to date. By 2026, cumulative reductions of 74% in ASR and 70% in deaths had already been achieved — benchmarks reached without vaccines in picture. Looking ahead, projections suggest further declines to 3.10 ASR and 450 deaths by 2043, continuing the natural and secular trajectory. This makes Australia the clearest example that the decline in HPV‑related cancer burden is primarily a product of natural clearance and healthcare systems, not vaccination, at least until post‑2027 data can be assessed and vaccines safety analysis emerges after 2026.